| Trial ID: | L0828 |
| Source ID: | NCT01930396
|
| Associated Drug: |
Tinzaparin
|
| Title: |
Use of Tinzaparin for Anticoagulation in Hemodialysis
|
| Acronym: |
HEMO-TIN
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Failure, Chronic
|
| Interventions: |
DRUG: Tinzaparin|DRUG: Unfractionated Heparin|DRUG: Placebo (for Tinzaparin)|DRUG: Placebo (for Unfractionated Heparin)
|
| Outcome Measures: |
Primary: Rate of major, clinically important non-major or minor bleeding, 26 weeks | Secondary: Clotting in extracorporeal dialysis circuit, During Hemodialysis (weekly for 26 weeks)
|
| Sponsor/Collaborators: |
Sponsor: Christine Ribic | Collaborators: McMaster University|LEO Pharma
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
191
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2013-09
|
| Completion Date: |
2016-09
|
| Results First Posted: |
|
| Last Update Posted: |
2016-10-14
|
| Locations: |
St. Joseph's Healthcare Hamilton, Hamilton, Ontario, L8N 4A6, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT01930396
|
